Stockholm, 4th October, 2017 – Peptonic Medical (publ) (‘Peptonic’ or ‘Company’) today announces that it has recruited Mr Erik Sundquist as VagiVital™ Brand Manager. In his role, Mr Sundquist will be responsible for the commercialisation of the Product – a vaginal gel developed in-house for the treatment of vaginal atrophy and vaginal dryness.
Mr Sundquist has many years of experience from marketing and sales of medical device products both nationally and internationally. From 2002 to 2006, Mr Sundquist held the position as Nordic Head and later as European Head at Q-Med. In these positions he was responsible for the sales of Q-Med’s products in paediatric urology, orthopaedics and urinary incontinence. In 2006, Mr Sundquist relocated to Hong Kong to build Q-Med’s organisation in Asia Pacific. This he accomplished with great success. In 2011, Mr Sundquist started his own consultancy business in Hong Kong focussing on medical devices and self-care products. Mr Sundquist is also founder of Medino Health, a Hong Kong based company that has developed a unique treatment method for hypertrophic scars and keloids. Since 2017, Mr Sundquist is back in Sweden with his family.
-We are very pleased to have Erik in our team, says Johan Inborr, CEO of Peptonic Medical. He has the experience, personality and knowledge required to successfully launch VagiVital™. Based on the strong treatment effect shown in the clinical studies, we believe that the product has great potential.
The Company is now in the process of obtaining CE-mark for VagiVital™, which is expected to be in place during the first quarter of 2018. First launch is planned in the summer of 2018.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 4th October 2017.
Peptonic Medical AB (publ) is an innovative Swedish biopharma company developing products within the field of women’s health. The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free product for the treatment of vaginal atrophy.
VagiVital® is a registered trademark of Peptonic Medical. The product is being developed for the non-prescription use for the treatment of vaginal atrophy.
Find out more at www.peptonicmedical.se
VagiVital™ is a self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results. The effect on symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. Peptonic plans to launch VagiVital™ as a non-prescription self-care product. More information can be found on www.peptonicmedical.se